CA2898644A1 - Composition for ophthalmic administration - Google Patents
Composition for ophthalmic administration Download PDFInfo
- Publication number
- CA2898644A1 CA2898644A1 CA2898644A CA2898644A CA2898644A1 CA 2898644 A1 CA2898644 A1 CA 2898644A1 CA 2898644 A CA2898644 A CA 2898644A CA 2898644 A CA2898644 A CA 2898644A CA 2898644 A1 CA2898644 A1 CA 2898644A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- compound
- buffer
- eye
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756306P | 2013-01-24 | 2013-01-24 | |
| US61/756,306 | 2013-01-24 | ||
| PCT/US2014/013036 WO2014117010A2 (en) | 2013-01-24 | 2014-01-24 | Composition for ophthalmic administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2898644A1 true CA2898644A1 (en) | 2014-07-31 |
Family
ID=50102221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2898644A Abandoned CA2898644A1 (en) | 2013-01-24 | 2014-01-24 | Composition for ophthalmic administration |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140206708A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2948130B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6351629B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2898644A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014117010A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| WO2017178892A2 (en) | 2016-04-14 | 2017-10-19 | M.G. Therapeutics Ltd. | Selenium disulfide compositions for use in treating meibomian gland dysfunction |
| CN107805212B (zh) * | 2017-11-03 | 2021-08-20 | 宿迁德威化工股份有限公司 | 一种2-甲基-5-氨基苯磺酰胺的制备方法 |
| EP4087655A4 (en) | 2020-01-10 | 2024-02-21 | Azura Ophthalmics Ltd | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1227128A (en) * | 1916-11-06 | 1917-05-22 | Ohio Blower Company | Conveying mechanism. |
| ZA815175B (en) * | 1980-08-01 | 1982-09-29 | Smith & Nephew Ass | Pharmaceutical composition |
| HU207222B (en) * | 1990-02-15 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing eyedrops containing primycin |
| CN1230882A (zh) * | 1996-09-20 | 1999-10-06 | 博士伦公司 | 再湿润隐形眼镜和减轻眼部干燥的方法和组合物 |
| JP5000835B2 (ja) * | 2000-08-25 | 2012-08-15 | 千寿製薬株式会社 | 水性懸濁液剤 |
| US20040198829A1 (en) * | 2001-04-23 | 2004-10-07 | Sponsel William Eric | Prostanoids augment ocular drug penetration |
| WO2008011836A2 (es) * | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Soluciones oftálmicas |
| WO2010008883A1 (en) * | 2008-06-24 | 2010-01-21 | Qlt Plug Delivery, Inc. | Combination treatment of glaucoma |
| CN102271915B (zh) * | 2008-11-04 | 2014-11-26 | 巴斯夫欧洲公司 | 复合箔作为氧化敏感性聚合物的包装材料的用途,包装氧化敏感性聚合物的方法以及含有所述复合箔的包装 |
| MX337849B (es) * | 2009-07-28 | 2016-03-09 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
| EP2595603A1 (en) * | 2010-07-21 | 2013-05-29 | Alcon Research, Ltd. | Pharmaceutical composition with enhanced solubility characteristics |
-
2014
- 2014-01-24 WO PCT/US2014/013036 patent/WO2014117010A2/en not_active Ceased
- 2014-01-24 US US14/163,948 patent/US20140206708A1/en not_active Abandoned
- 2014-01-24 JP JP2015555360A patent/JP6351629B2/ja not_active Expired - Fee Related
- 2014-01-24 CA CA2898644A patent/CA2898644A1/en not_active Abandoned
- 2014-01-24 EP EP14704453.1A patent/EP2948130B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014117010A3 (en) | 2015-01-29 |
| JP6351629B2 (ja) | 2018-07-04 |
| JP2016506931A (ja) | 2016-03-07 |
| EP2948130A2 (en) | 2015-12-02 |
| US20140206708A1 (en) | 2014-07-24 |
| WO2014117010A2 (en) | 2014-07-31 |
| EP2948130B1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2768543C (en) | Compositions and methods for inhibition of the jak pathway | |
| EP2788028B1 (en) | Topical formulation for administering a compound | |
| JP2018115205A (ja) | 白斑の治療法 | |
| EA032694B1 (ru) | Ингибитор киназ | |
| ES2686532T3 (es) | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide | |
| EP2948130B1 (en) | Composition for ophthalmic administration | |
| JP2019534269A (ja) | Csf−1rの阻害剤を使用して眼疾患を治療するための方法 | |
| CN107106566A (zh) | 晶状体硬化抑制剂 | |
| JPWO2018199224A1 (ja) | 抗アレルギー剤 | |
| HK1193746A (en) | 2,4 substituted pyrimidinediamines for use in discoid lupus | |
| HK1193746B (en) | 2,4 substituted pyrimidinediamines for use in discoid lupus | |
| CN106456641A (zh) | 眼后段疾病的预防或治疗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190114 |
|
| FZDE | Discontinued |
Effective date: 20210831 |